Site en français

Evaluation and mechanism of action of novel anticancer targeted drugs: Dasatinib, a tyrosine kinase inhibitor in melanoma.

Units : Laboratory of Oncology and Experimental Surgery | ULB305

Description :

Evaluation of the cytotoxic effect and molecular mechanisms associated with the sensitivity to the tyrosine kinase inhibitor
dasatinib in a panel of melanoma cell lines established from metastatic tissue. Identification of markers to select melanoma patients
who would benefit from dasatinib therapy.

List of persons in charge :

  • GHANEM Ghanem Elias

  • JOURNE Fabrice

List of lessors :

  • Organisations internationales

  • Autres ressources extérieures